A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study of the Safety and Efficacy of 2 Doses of Tigecycline Versus Imipenem/Cilastatin for the Treatment of Subjects With Hospital-Acquired Pneumonia.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tigecycline (Primary) ; Imipenem/cilastatin
Indications Nosocomial pneumonia; Pseudomonal infections; Staphylococcal infections; Ventilator associated pneumonia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
03 Apr 2012 Results presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
11 Aug 2011 Planned end date changed from Jan 2013 to Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight